This move is archived. Current quotes and coverage live on the stock page.
Get HLS alerts:
HLS Therapeutics Inc faces a challenging day on the TSX, with shares sliding nearly 1%.
HLS Therapeutics Inc (HLS.TO) has seen its stock price decline by 0.91% in the latest trading session, closing at CA$4.35. This downturn raises questions about the company's recent performance and investor sentiment, especially as it navigates a competitive landscape in the pharmaceutical sector.
Investor takeaway: Despite a slight revenue increase reported in Q1 2026, the stock's recent performance suggests that investors may be cautious about future growth prospects.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$116.01M
52W high
$5.76
52W low
$3.56
1W change
+3.61%
Beta
0.83
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 95.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.30
+95.6% Upside
Current Price
C$3.73
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
36.8%
Annualized
90-Day Vol
29.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.12
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.51 | C$3.10 โ C$3.99 |
| 60 trading days | C$3.31 | C$2.77 โ C$3.96 |
| 90 trading days | C$3.12 | C$2.50 โ C$3.89 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
HLS Therapeutics Inc down 0.91% today
The company's market cap stands at CA$134.48 million, reflecting investor uncertainty in the face of modest revenue growth.
Bull case
HLS Therapeutics has shown some positive momentum with a 2% year-over-year revenue increase in its latest quarterly report, indicating potential for recovery.
Bear case
The company continues to face challenges, including a negative profit margin and a lack of significant news to boost investor confidence, which contribute to its current stock weakness.
Market Performance Overview
Advertisement
HLS Therapeutics Inc's stock has experienced a decline of 0.91% in the last trading session, closing at CA$4.35. This drop raises concerns among investors, especially given the company's recent financial results that showed only modest growth.
Recent Financial Results
In its Q1 2026 report, HLS Therapeutics announced a revenue increase of 2% year-over-year, reaching CA$12.9 million. However, the market's reaction suggests that investors are looking for more substantial growth and profitability, given the company's current profit margin of -0.1846.
Investor Sentiment and Future Outlook
With a market cap of CA$134.48 million, HLS Therapeutics faces scrutiny from investors who are concerned about its long-term growth prospects. The lack of significant news or developments may leave the stock vulnerable to further declines unless the company can demonstrate more robust financial health.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
